RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
31 Luglio 2023 - 2:30PM
Business Wire
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a
clinical-stage biopharmaceutical company developing targeted
combination therapies, today announced that its CEO Shaun Bagai
will provide a corporate overview and update at the 43rd Annual
Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at
10:30 AM ET in Boston, MA. Register here to access the live
webcast.
Mr. Bagai will discuss recent Company milestones, including the
research collaboration with Imugene (ASX: IMU), and highlights from
RenovoRx’s open label pivotal Phase III TIGeR-PaC study. The
TIGeR-PaC study is evaluating the proprietary TAMP™ (Trans-Arterial
Micro-Perfusion) therapy platform for the treatment of locally
advanced pancreatic cancer (LAPC). Interim data demonstrates a
6-month overall survival benefit, 8-month delay in cancer
progression, and 65% reduction in adverse effects over systemic
(intravenous) chemotherapy. The data, presented at the recent 2023
ESMO World Congress on Gastrointestinal Cancer, drove the decision
from the TIGeR-PaC Data Monitoring Committee (DMC) to continue this
pivotal trial.
43rd Annual Canaccord Genuity Growth
Conference Date: August 10, 2023 Time:
10:30 – 10:55 AM ET Speaker: Shaun Bagai, CEO of RenovoRx
Location: Boston, Massachusetts Webcast:
https://wsw.com/webcast/canaccord89/rnxt/2519572
To schedule a one-on-one investor meeting with RenovoRx’s
management team, please contact a conference representative or KCSA
Strategic Communications at RenovoRx@KCSA.com.
A webcast of the event will be available for a limited time in
the Investors section of the Company’s website.
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company
developing targeted combination therapies for high unmet medical
needs. The Company’s proprietary Trans-Arterial Micro-Perfusion
(TAMP™) therapy platform is designed to bypass traditional systemic
delivery methods and ensure precise therapeutic delivery to a
target tissue, while minimizing a therapy’s systemic toxicities.
RenovoRx’s unique approach to drug-delivery offers the potential
for increased treatment safety, tolerance, and wider therapeutic
windows. The Company’s lead product candidate, RenovoGem™ combines
gemcitabine with the company’s patented delivery system and is
regulated by FDA under the IND 21 CFR 312 pathway. RenovoGem is
currently in a Phase III clinical trial (TIGeR-PaC) for the
treatment of locally advanced pancreatic cancer, where interim
analysis has demonstrated a 6-month overall survival benefit,
8-month delay in cancer progression, and 65% reduction in adverse
effects over systemic (intravenous) chemotherapy. RenovoRx is
committed to transforming the lives of patients by delivering
innovative solutions to change the current paradigm of cancer care.
RenovoGem is currently under investigation for TAMP therapeutic
delivery of gemcitabine and has not been approved for commercial
sale.
For more information, visit www.renovorx.com. Follow RenovoRx on
Facebook, LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230731606568/en/
Investor Contact: KCSA Strategic Communications Valter
Pinto or Jack Perkins T:212-896-1254 renovorx@kcsa.com
Media Contact: KKH Advisors Kimberly Ha T: 917 291-5744
kimberly.ha@kkhadvisors.com
Grafico Azioni RenovoRx (NASDAQ:RNXT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni RenovoRx (NASDAQ:RNXT)
Storico
Da Giu 2023 a Giu 2024